Cougar Biotech Board Backs J&J's $894M Bid
LOS ANGELES (AP) — Cougar Biotechnology Inc.'s board on Friday recommended shareholders approve takeover offer worth almost $894 million from Johnson & Johnson, which launched a cash tender offer to buy all shares of the clinical-stage developer of cancer treatments.
The $43-per-share offer would provide Cougar Biotechnology shareholders a slight premium over the stock's closing price of $42.93 on Thursday. The offer values the company at $893.7 million, based on the 20,784,120 common shares that Cougar Biotechnology listed as outstanding as of May 4 in its latest regulatory filing. Shares of Cougar Biotechnology slipped 3 cents to $42.90 in morning trading Friday. Shares of New Brunswick, N.J.-based J&J fell 51 cents to $55.32. Los Angeles-based Cougar said its board unanimously recommended acceptance of the bid, and the directors plan to tender all their shares in favor a transaction expected to close in the third quarter. The acquisition is subject to various closing conditions. J&J, a diversified health products company, said it was making the offer through a new wholly owned subsidiary, Kite Merger Sub Inc. J&J announced its intent to acquire Cougar Biotechnology on May 21, and launched the tender offer Friday.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,388.90 | 1,105.98 | 2,194.35 | 34.83 |
Oil *
77.74
|
|
UP
22.75
|
UP
6.06
|
UP
21.21
|
UP
1.03
|
10 Yr
3.48%
SPDR Gold
113.75
|
|
+0.22%
|
+0.55%
|
+0.98%
|
+3.05%
|
Data delayed 20 minutes |














